(S)-2-phenylpent-4-en-1-ol | 265656-12-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (S)-2-phenylpent-4-en-1-ol
• 英文别名: (2S)-2-phenylpent-4-en-1-ol
• CAS: 265656-12-0
• 化学式: C₁₁H₁₄O
• 分子量: 162.232
• InChiKey: YZQOZSHPDOZAGU-LLVKDONJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  间溴苯甲醚 、 (S)-2-phenylpent-4-en-1-ol 在 Pd-based catalyst 、 双(2-二苯基磷苯基)醚 、 sodium t-butanolate 作用下， 生成 、
  参考文献：
  名称：

  Influence of Hydroxylamine Conformation on Stereocontrol in Pd-Catalyzed Isoxazolidine-Forming Reactions

  摘要：

  Palladium-catalyzed carboamination reactions between N-Boc-O-(but-3-enyl)hydroxylamine derivatives and aryl or alkenyl bromides afford cis-3,5- and trans-4,5-disubstituted isoxazolidines in good yield with up to >20:1 dr. The diastercoselectivity observed in the formation of cis-3,5-disubstituted isoxazolidines is superior to selectivities typically obtained in other transformations, such as 1,3-dipolar cycloaddition reactions, that provide these products. In addition, the stereocontrol in the C-N bond-forming Pd-catalyzed carboamination reactions of N-Boc-O-(but-3-enyl)hydroxylamines is significantly higher than that of related C-O bond-forming carboetherification reactions of N-benzyl-N-(but-3-enyl)hydroxylamine derivatives. This is likely due to a stereoelectronic preference for cyclization via transition states in which the Boc group is placed in a perpendicular orientation relative to the plane of the developing ring, which derives from the conformational equilibria of substituted hydroxylamines.

  DOI：

  10.1021/jo8027399
• 作为产物：
  描述：

  (S)-4,4,5,5-tetramethyl-2-(2-phenylpent-4-en-1-yl)-1,3,2-dioxaborolane 在 sodium perborate tetrahydrate 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 12.0h， 生成 (S)-2-phenylpent-4-en-1-ol
  参考文献：
  名称：

  Cu/Pd协同催化烯烃对映选择性烯丙基硼化反应

  摘要：

  报道了一种合作的 Cu/Pd 催化的苯乙烯、B2(pin)2 和烯丙基碳酸酯的不对称三组分反应。该反应在手性 CuOAc/SOP 和非手性 Pd(dppf)Cl 2 催化剂存在下以高对映选择性（高达 97% ee）平稳发生。烯丙基硼化产物含有烯烃（或二烯）单元和烷基硼基团，易于官能化。该协议的效用通过抗精神病药物 (-)-preclamol 的合成得到证明。

  DOI：

  10.1021/jacs.5b09146

文献信息

• BENZAMIDE POTASSIUM CHANNEL INHIBITORS
  申请人：Merck & Co., Inc.

  公开号：EP1126836A1

  公开（公告）日：2001-08-29
• EP1126836A4
  申请人：——

  公开号：EP1126836A4

  公开（公告）日：2002-09-04
• COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
  申请人：AMGEN INC.

  公开号：US20210230189A1

  公开（公告）日：2021-07-29

  Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
• US6194458B1
  申请人：——

  公开号：US6194458B1

  公开（公告）日：2001-02-27
• [EN] BENZAMIDE POTASSIUM CHANNEL INHIBITORS<br/>[FR] INHIBITEURS BENZAMIDIQUES DE CANAUX POTASSIQUES
  申请人：MERCK & CO INC

  公开号：WO2000025774A1

  公开（公告）日：2000-05-11

  This invention relates to benzamide potassium channel inhibitors of general structural formula (I). The compounds of this invention are useful in the treatment of autoimmune diseases, the prevention of rejection of foreign organ transplants and related afflictions, diseases and illnesses, and cardiac arrhythmias. Also within the scope of this invention are pharmaceutical formulations comprising a compound of formula (I) and a pharmaceutical carrier, as well as pharmaceutical formulations comprising a compound of formula (I), one or more immunosuppressive compounds and a pharmaceutical carrier.